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Tacrolimus (Tac) exhibits an interindividual pharmacokinetic
variability that affects the dose required to reach the target
concentration in blood. Tac is metabolized by two enzymes
of the cytochrome P450 family, CYP3A5 and CYP3A4. The
effect of the CYP3A5 genotype on Tac bioavailability has
been demonstrated, and the main determinant of this
pharmacogenetic effect is a single-nucleotide polymorphism
(SNP) in intron 3 of CYP3A5 (6986 A4G; SNP rs776746; also
known as CYP3A5*3). The mean dose-adjusted blood Tac
concentration was significantly higher among CYP3A5*3
homozygotes than that of carriers of the wild-type allele
(CYP3A5*1). In a recent prospective study, a group of kidney
transplant patients received a Tac dose either according to
the CYP3A5 genotype (the adapted group) or according to
the standard regimen (the control group). All patients
received induction therapy with mycophenolate mofetil,
corticosteroids, and either basiliximab or intravenous
anti-thymocyte globulin. Patients in the adapted-dose group
required 3–8 days (median 6 days) to reach the target range
compared with 3–25 days (median 7 days) in the control
group (P¼ 0.001). The total number of dose modifications
was also lower in the adapted-dose group. This study also
suggested that the CYP3A5 genotype might contribute
minimally to the reduction of early acute rejection. However,
additional studies are necessary to determine whether the
pharmacogenetic approach could help reduce the necessity
for induction therapy and co-immunosuppressors.
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The current immunosuppressive therapy in solid organ
transplantation uses a combination of several drugs that
function on multiple pathways of the immune response.
These drugs are classified by their mechanism of action, such
as calcineurin inhibitors (cyclosporine A, tacrolimus (Tac)),
inhibitors of purine synthesis (mycophenolate mofetil), and
mammalian target of rapamycin inhibitors (sirolimus,
everolimus). These drugs are frequently combined with
glucocorticoids (methylprednisolone, prednisone), mono-
clonal (muromonab, basiliximab, daclizumab), and poly-
clonal (anti-thymocyte globulin) antibodies.
Tacrolimus is an immunosuppressive drug used to prevent
solid organ rejection, and also to treat autoimmune diseases.
Tac, similar to cyclosporine, is a calcineurin inhibitor and
suppresses the activation, proliferation, and differentiation of
T cells. Calcineurin inhibitors prevents the transcription of
several cytokine genes involved in immune responses.1–3 Tac
has gradually replaced cyclosporine as the first-choice
immunosuppressive drug, mainly because of its higher
immunosuppressive activity and fewer adverse effects.
However, Tac has also been associated with a higher risk of
developing dyslipidemia, hypercholesterolemia, hyperten-
sion, post-transplant (PT) nephrotoxicity, and new-onset
diabetes after transplantation.4–7
Tac shows an interindividual pharmacokinetic variability
that affects the dose required to reach the target concentra-
tion in blood.8,9 The current therapeutic approach is based
on an initial daily dose of 0.2mg/kg (given in two equal 12-h
doses in the case of Prograf (Astellas Pharma, Deerfield, IL)).
The blood level is measured 12 h after dose (immediately
before receiving the next dose) and is known as the trough or
C0 level. The clinician uses the C0 level in each individual
patient to decide whether to maintain, increase, or reduce the
dose.9,10 The target C0, which is 10–15 ng/ml in the period
0 to 3 months PT, and 5–10 ng/ml thereafter, is considered as
the optimal concentration to avoid rejection (a concentration
too low) and toxicity (a concentration too high).10
Mainly, Tac is metabolized by two enzymes of the
cytochrome P450 family, CYP3A5 and CYP3A4, whereas
other P450 isoforms are much less effective.11–13 Most of the
Tac biotransformation occurs in the liver, and to a lesser
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extent in the small intestine. In vitro studies with human liver
microsomes showed that CYP3A5 had high Tac catalytic
efficiency, and its contribution was stronger in microsomes
from individuals with low CYP3A4 concentrations.11 Several
factors influence the blood concentration of Tac. Some
factors are under the patients’ control, such as diet or the
co-administration of drugs that share the same metabolic
pathways with Tac (i.e., fluconazole and ketoconazole).14,15
However, some of the major determinants of Tac bioavail-
ability reside in genes implicated in its absorption and
metabolization. Several studies have reported that poly-
morphisms at the ABCB1/MDR-1, CYP3A4, and CYP3A5
affect Tac dose requirements, as discussed below.
CYP3A5 IN Tac DOSE
The effect of the CYP3A5 genotype on Tac bioavailability has
been demonstrated by several laboratories.16–24 The main
determinant of this pharmacogenetic effect is a single-nucleotide
polymorphism (SNP) in intron 3 of CYP3A5 (6986 A4G; SNP
rs776746), also known as CYP3A5*3 (for a complete list of the
CYP variants, see the home page of the Human Cytochrome
P450 Allele Nomenclature, http://www.cypalleles.ki.se).25,26 Most
studies examined the effect of CYP3A5*3 on the twice-daily dose
formulation of Tac (Prograf) at several PT times. The mean
dose-adjusted blood Tac concentration was significantly higher
among CYP3A5*3 homozygotes than that of carriers of the
wild-type allele (CYP3A5*1). The CYP3A5*3 allele affects
splicing of the pre-mRNA and greatly reduces P450-3A5
activity.11,12 The poor metabolizing phenotype of CYP3A5*3/*3
homozygotes explains why they would require a lower Tac dose
to reach the blood target concentration compared with carriers
of the CYP3A5*1 allele.
We recently reported the results of a multicenter study of
Tac-pharmacogenetics in Spanish patients who received a
first cadaveric kidney graft (the REDinREN pharmacogenetic
study).24 A total of 400 patients were treated with a standard
triple immunosuppressive therapy with Tac (Prograf),
prednisone, and mycophenolate mofetil. The initial oral
dose of Tac was 0.2mg/kg per day and was adjusted to reach a
C0 of 10–15 ng/ml in the period from 0 to 3 months PT, and
5–10 ng/ml thereafter. Tac was measured in human whole
blood with an automated chemiluminescent immunoassay
and the Arquitect Tacrolimus assay (Abbott Laboratories,
Chicago, IL).27 Compared with CYP3A5*1 carriers (n¼ 80),
patients who were CYP3A5*3 homozygotes (n¼ 320) re-
ceived lower median Tac (mg/kg per day) at 1 week (0.14 vs
0.12), at 6 months (0.10 vs 0.06), and at 1 year (0.08 vs 0.05)
PT. These values were similar to those reported by others.
Assessing the impact of the CYP3A5*3 allele on Tac
pharmacogenetics needs to consider the genotype frequencies
among populations of various ethnic origins. Approximately
80% of Caucasians, but only 30% of African Americans, are
CYP3A5*3 homozygotes (non-expressors).28 These differ-
ences in genotype frequencies could explain part of the
observed variability in Tac dose requirements among
different populations.29
CYP3A4 IN Tac DOSE
A number of CYP3A4 SNPs have been identified. Most of the
interindividual variability in CYP3A4 activity may be due to
differences in transcript levels, and results from nucleotide
changes in the promoter region.30 In particular, the
CYP3A4*1B (392A4G; SNP rs2740574) is a common
allele located in the promoter region, is associated with
differences in transcriptional activity, and correlates with
increased hepatic expression of CYP3A4.31,32
Its expression varies in liver and other tissues, and its
inherent concentration has a role on Tac metabolism in liver
microsomes, particularly in microsomes from individuals
who did not express CYP3A5.11 However, none of CYP3A4
SNPs has shown a clear influence on Tac pharmacokinetics.33
In our study, carriers of the 392 A4G variant had
significantly higher Tac doses.24 A higher gene expression
linked to this allele (compared with the wild type, CYP3A4*1)
could explain the lower dose requirements among CYP3A4*1
homozygotes. Although our work confirmed the results from
other studies,24 the significance of our study was limited by
the low frequency of the CYP3A4*1B allele (only 6% of the
patients were CYP3A4*1B carriers, and no patient was
homozygous for this allele). However, CYP3A4 and CYP3A5
are closely linked, and the effect of the CYP3A4 polymorph-
isms on Tac pharmacokinetics could be due to linkage
disequilibrium with CYP3A5*3. A way to solve this dilemma
is to analyze the effect of CYP3A4 variation on patients with
different CYP3A5 genotypes.
CYP3A4*1B carriers had significantly higher median Tac
C0 values at 3 and 1 year PT, but not at 7 days PT than
CYP3A4*1 homozygotes did. The same modifying effect of
the CYP3A4 genotype was observed among CYP3A5*1
carriers.24 In contrast, Kuypers et al.23 reported similar Tac
C0 values for the two CYP3A5*1 groups. However, no patient
in their study was a CYP3A5*3 homozygoteþCYP4A4*1B
carrier. Because the conclusions of these studies are
hampered by the low number of patients who were
CYP3A5*1B carriers, additional studies with larger cohorts
of patients are necessary to determine the value of genotyping
CYP3A4 in addition to CYP3A5.23,24
ABCB1 POLYMORPHISMS IN Tac DOSE
The ABCB1 gene (also known as the multidrug resistance-1
gene, MDR-1) encodes the P-glycoprotein (P-gp), which is a
pump that drives the efflux of many drugs in the intestinal
wall and other cell types. The amount of the drug that reaches
the blood stream could depend on the P-gp activity, and
ABCB1 polymorphisms linked to differences in P-gp expres-
sion/function could have an important role on dose
requirements.33–38 The role of P-gp expression on Tac
bioavailability was reported by Masuda et al.,39 who found
a strong correlation between ABCB1 mRNA levels in
intestinal biopsies and the dose-adjusted Tac concentrations.
The effect of several ABCB1 SNPs on Tac pharmacokinetics
has been investigated, with conflicting results.17–23 We did not
find a significant effect of the common c.3435 C/T
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polymorphism (exon 26 SNP rs1045642) on Tac bioavail-
ability.24 In addition, this SNP did not modify the effect of
the CYP3A5 genotype.
However, the donor ABCB1 3435TT genotype was
significantly associated with susceptibility to chronic allograft
damage.40 The 3435 T homozygosity likely increased the
renal expression of P-gp, which resulted in intrarenal
accumulation of Tac.40 If this result is confirmed by others,
the donor ABCB1 genotype could be a valuable tool to
predict Tac-induced nephrotoxicity.
OTHER GENE VARIANTS IN Tac DOSE
Although the CYP3A5*3 is the main genetic determinant of
Tac pharmacokinetics, this SNP explains B50% of the total
variability.20 Thus, other genetic variants could affect Tac
metabolism and dose requirements. The effect of other
nucleotide variants could also explain the variability between
individuals with the same CYP3A5 genotype. For instance,
41% of our CYP3A5*3/*3 and 26% of the CYP3A5*1 carriers
had C0 values in the target range (10–15 ng/ml) at 1 week PT.
Although these frequencies diminished with time, 10% of
the patients remained out of the target range (5–10 ng/ml)
after 6 months PT. Data regarding the possible role of several
polymorphisms on Tac pharmacogenetics have been recently
presented.41 We assessed the effect of 96 DNA variants in 16
metabolizing enzymes on Tac dose requirements.24 In
addition to CYP3A4, CYP3A5, and ABCB1, several P450,
glutathione and N-acetyl transferases, and thiopurine
S-methyltransferase gene variants were studied. We did
not detect any significant effects of these SNPs on Tac
dose requirements. Moreover, none of these polymorphisms
had a significant effect after correcting for the CYP3A5
genotype.
The CYP3A4 polymorphisms may also affect Tac pharma-
cokinetics. As discussed above, our data suggested an effect of
the CYP3A4*1B allele on Tac metabolism. At 1 year PT, the
patients who were CYP3A5*3*3þCYP3A4*1B carriers had
Tac C0 values in the target range, whereas 6% of the
CYP3A5*3/*3þCYP3A4*1/*1 remained out of the target
range.24 Most of the CYP3A4 variants found in the coding
region have an allele frequency o1%. An exception was
CYP3A4*2, a missense SNP (Ser222Pro) with a frequency of
5% among the Caucasians. This allele was linked to a lower
clearance of the CYP3A4 substrate nifedipine, and carriers of
this allele can thus be classified as ‘slow metabolizers’.42,43 The
effect of this variant on Tac bioavailability has not been
established. The sequencing of CYP3A4 may be very
informative in patients whose C0 values cannot be explained
by the CYP3A5 genotype, and the sequencing can help
determine the overall contribution of CYP3A4 to Tac dose
requirements. The same argument applies for the sequencing
of CYP3A5 in those patients who are CYP3A5*1 carriers with
C0 values that were above the target range. These patients
could harbor one of several CYP3A5 variants that are linked
to a reduced catalytic activity and a slow to null metabolizing
phenotype.
READY FOR CLINICAL TRANSLATION?
The ultimate goal of the pharmacogenetics of Tac is to
provide a tool to predict the dose for each patient before
transplantation, and prevent the effects induced by an over/
underdose. Haufroid et al.20 proposed a loading dose of
0.075mg/kg and 0.150mg/kg body weight twice a day among
CYP3A5 non-expressors and expressors, respectively. These
values were derived from a study of 19 volunteers (nine
expressors, 10 non-expressors) who received a standard dose
(0.1mg/kg body weight twice a day). This and other studies
paved the way toward clinical trials that evaluate the benefit
of dosing according to the genotype.44
The first prospective study has been recently reported by
Thervet et al.45 A group of 280 patients received a Tac dose,
either according to the CYP3A5 genotype (the adapted-dose
group; n¼ 116) or to the standard regimen (the control
group; n¼ 120). All patients received induction therapy with
mycophenolate mofetil (Cell-Cept; Roche Farma, Basel,
Switzerland), corticosteroids, and either basiliximab (Simu-
lect; Novartis, Basel, Switzerland) or intravenous anti-
thymocyte globulin (Thymoglobulin; Genzyme, Cambridge,
MA). No drugs known to interact with CYP3A5 were
administered. A limitation of this study was that Tac
administration began on day 7 PT (a time required to
determine the genotype), and the effect of the pharmacoge-
netic adaptation was thus not evaluated in patients treated
with Tac from day 0. This delay in Tac dosing could affect the
main clinical and analytical findings.
At day 7 PT, the patients in the adapted-dose group who
were CYP3A5 expressors (n¼ 26) received an initial Prograf
dose of 0.30mg/kg per day, compared with 0.15mg/kg per
day among the CYP3A5 non-expressors (n¼ 90). The control
group was treated with an initial dose of 0.20mg/kg per day.
The first measurement of the Tac C0 concentration was
recorded after the sixth Tac dose (on day 10 PT). Patients in
the adapted-dose group had Tac C0 values in the target range
(10–15 ng/l) more frequently than the control group (43.3 vs
29.2%; P¼ 0.003). Moreover, the adapted-dose group
required 3–8 days (median 6 days) to reach the target range
compared with 3–25 days (median 7 days) in the control
group (P¼ 0.001). The total number of dose modifications
was also lower in the adapted-dose group (281 vs 420;
P¼ 0.004). This study provided the first evidence that the
genotyping-based dose adaptation reduces the time to reach
the blood target concentration, but was this the only benefit?
Tac blood levels are routinely monitored several times in
the first few weeks PT to adjust the dose to the target
concentration, which is achieved within the first 2 weeks in
B90% of the patients. Therefore, it should not be surprising
that clinicians may consider that the adapted-dose method
requires too much effort if the only benefit is to more rapidly
(few days) determine the right dose.46 The significant delay
in achieving the target blood concentration among CYP3A5
expressors has been linked to higher risk for early acute
rejection.47–49 However, some authors failed to confirm
the association between the CYP3A5*1 allele and acute
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rejection.50,51 Thervet et al.45 did not find significant differences
in the incidence of delayed graft function, the number of PT
dialysis sessions per patient, or the number of acute rejection
episodes between the adapted and control groups. Their
findings suggested that the Tac dose according to the CYP3A5
genotype might contribute minimally to the reduction of early
acute rejection. However, the fact that their patients received
biological induction therapy coupled with high dose of MMF
during the first week could significantly reduce the incidence of
acute rejection, affecting the results of the study. It is thus
important to replicate this study on patients treated with an
adapted dose from day 0, and also to determine whether the
pharmacogenetic approach could help reduce the necessity for
induction therapy and co-immunosuppressors.
Finally, recent studies have also demonstrated a significant
effect of the CYP3A5 genotype on the pharmacokinetic and
dose requirements for the once-daily Tac formulation
(Advagraf, Astellas Pharma, Staines, UK).52,53 These results
suggested that the pharmacogenetic approach for the twice-
daily formulation could be also applied to this once-daily
formulation, which may improve patient compliance.
In conclusion, genotyping of CYP3A5 may be useful to
predict the Tac dose immediately after transplantation, and
reduce the time required to reach the target concentration.
However, the effect of the genotype-adapted dose on acute
rejection and other clinical outcomes seems less clear.
Therefore, trials to determine whether this pharmacogenetic
approach could reduce the incidence of acute rejection and
delayed graft function are necessary, particularly in patients
without biological induction therapy.
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